Brad Schaeffer MedComp

Brad Schaeffer of Medcomp Sciences says Testing still Vital ahead of Vaccine Availability

Brad Schaeffer of Medcomp Sciences

Public interest in medicine, testing, side effects and availability has never been so high. We can thank the coronavirus pandemic for that. If anything, this health crisis has helped strengthen the bond between patients and clinical scientists doing difficult work in laboratories across the globe. Brad Schaeffer, Medcomp Sciences’ president and CEO, is no stranger to that line of work. He’s been at the helm of this medical/clinical diagnosis laboratory since mid-2012 and has helped provide clients with testing products that explain the condition of a patient. His company is currently providing two forms of tests, which will discuss below, to detect the presence of COVID-19 antibodies. With the roll-out of vaccines now under way, Brad Schaeffer of Medcomp Sciences wants readers to understand the intricate work that lies ahead.

Getting shots of the COVID-19 vaccine out to the general public entails a number of logistical hurdles. Chief among them is temperature, which is something clinical technicians will be familiar with. According to the Centers for Disease Control, the Moderna vaccine will arrive to distributors still frozen and must be stored in a freezer that maintains a temperature between -13 and 5 degrees Fahrenheit. “If storing the vaccine in a freezer with routinely recommended vaccines, carefully adjust the freezer temperature to the correct temperature range for this vaccine,” the CDC advises, adding that dry ice should not be used for storage and keeping the vials out of direct sunlight is also important.

These protocols from the CDC barely scratch the surface of efforts that have gone into creating a virus vaccine in a record-shattering amount of time. Brad Schaeffer of Medcomp Sciences is confident that the tests provided by his clinical laboratory gave vaccine developers just a little bit more breathing room to roll out their product. The two tests offered are Active Infection Genetic and Immune Response Antibody. The former test would tell doctors that the patient is currently infected with the COVID-19 virus while the latter would show a previous infection due to the presence of antibodies. Knowing that someone is currently infected and having them quarantine away from the general population has been instrumental in slowing the spread of the disease and keeping infection rates from spiking out of control.

Brad Schaeffer of Medcomp Sciences further points to boots-on-the-ground efforts by his company, which included free testing at Louisiana’s Zachary Youth Park in May 2020. Mr. Schaeffer says these offerings are all part of the puzzle to keep people safe and healthy until fellow clinical scientists can work on widespread vaccinations.

By Brad Schaeffer MedComp

Brad Schaeffer of MedComp Sciences covers news in the life sciences industry.

Leave a Reply

Your email address will not be published. Required fields are marked *